The Role of the Plasmodium falciparum Chloroquine Resistance Transporter Gene in Malaria Drug Resistance and its implication on malaria control in Africa

Background: Malaria remains a pressing public health issue in Africa, with Plasmodium falciparum being the primary cause of severe cases. The emergence of drug-resistant strains, particularly those associated with Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene mutations has significantly hampered malaria control efforts. Methods: This review delves into the public health implications of pfcrt gene mutations, focusing on their role in chloroquine resistance and the broader impacts on malaria treatment and control in Africa. Results: Key mutations in the Pfcrt gene, notably the K76T mutation, have compromised the efficacy of chloroquine, a drug that was once fundamental to antimalarial treatment. These mutations significantly reduce the drug’s accumulation within the parasite’s digestive vacuole, leading to treatment failures and an increased disease burden. Moreover, the K76T mutation and other polymorphisms play a crucial role in cross-resistance against other antimalarial drugs, adding a layer of complexity to treatment strategies. Conclusion: Addressing the public health challenges associated with pfcrt mutations requires a multifaceted approach, including enhanced surveillance, innovative drug development, and effective community education. However, the persistence of Pfcrt mutations poses a significant threat to malaria control and eradication efforts, necessitating the development of new therapeutic approaches and the enhancement of existing strategies. Continued research and investment in these areas are crucial for overcoming resistance challenges and achieving sustained success in malaria control and eradication in Africa.